TWI880995B - 急性骨髓性白血病或骨髓發育不良症候群的治療 - Google Patents

急性骨髓性白血病或骨髓發育不良症候群的治療 Download PDF

Info

Publication number
TWI880995B
TWI880995B TW109142965A TW109142965A TWI880995B TW I880995 B TWI880995 B TW I880995B TW 109142965 A TW109142965 A TW 109142965A TW 109142965 A TW109142965 A TW 109142965A TW I880995 B TWI880995 B TW I880995B
Authority
TW
Taiwan
Prior art keywords
compound
dose
days
myeloid leukemia
treatment
Prior art date
Application number
TW109142965A
Other languages
English (en)
Chinese (zh)
Other versions
TW202134237A (zh
Inventor
馬克 Ｒ 布雷
賈桂林 Ｍ 曼森
葛漢 佛勒雀
Original Assignee
加拿大健康網路大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 加拿大健康網路大學 filed Critical 加拿大健康網路大學
Publication of TW202134237A publication Critical patent/TW202134237A/zh
Application granted granted Critical
Publication of TWI880995B publication Critical patent/TWI880995B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW109142965A 2019-12-06 2020-12-04 急性骨髓性白血病或骨髓發育不良症候群的治療 TWI880995B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962944876P 2019-12-06 2019-12-06
US62/944,876 2019-12-06

Publications (2)

Publication Number Publication Date
TW202134237A TW202134237A (zh) 2021-09-16
TWI880995B true TWI880995B (zh) 2025-04-21

Family

ID=76221282

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109142965A TWI880995B (zh) 2019-12-06 2020-12-04 急性骨髓性白血病或骨髓發育不良症候群的治療

Country Status (12)

Country Link
US (1) US12533357B2 (enExample)
EP (1) EP4069246A4 (enExample)
JP (1) JP2023505301A (enExample)
KR (1) KR20220124177A (enExample)
CN (1) CN115397429A (enExample)
AU (1) AU2020396807B2 (enExample)
BR (1) BR112022011052A2 (enExample)
CA (1) CA3163796A1 (enExample)
IL (1) IL293623A (enExample)
MX (1) MX2022006910A (enExample)
TW (1) TWI880995B (enExample)
WO (1) WO2021108918A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7337539B2 (ja) * 2018-06-21 2023-09-04 メディヴィル・アクチエボラーグ 白血病療法のための塩基修飾シチジンヌクレオチド
TWI926033B (zh) 2021-05-11 2026-05-21 美商歐瑞克製藥公司 類ｐｏｌｏ激酶４抑制劑
TW202333712A (zh) * 2021-12-22 2023-09-01 加拿大健康網路大學 於急性骨髓性白血病或淋巴瘤之治療
CN117180295A (zh) * 2023-09-13 2023-12-08 华东医院 一种用于治疗tp53突变髓系肿瘤的药物组合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019046949A1 (en) * 2017-09-08 2019-03-14 University Health Network POLYTHERAPIES FOR INHIBITING KINASE 4 OF THE POLO TYPE

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010115279A1 (en) 2009-04-06 2010-10-14 University Health Network Kinase inhibitors and method of treating cancer with same
TWI516262B (zh) 2010-04-06 2016-01-11 健康網路大學 激酶抑制劑及以其治療癌症的方法
CA2803446C (en) * 2010-07-02 2019-06-04 University Health Network Use of plk4 antagonists for treating pten mutant diseases
WO2012048411A1 (en) * 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
EP3052102B1 (en) 2013-10-04 2019-12-04 Aptose Biosciences Inc. Compositions for treating cancers
TR201902875T4 (tr) * 2013-10-18 2019-03-21 Univ Health Network Plk-4 inhibitörünün tuz ve kristal formları.
WO2015116696A1 (en) 2014-01-28 2015-08-06 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
KR20190129889A (ko) 2017-03-31 2019-11-20 노파르티스 아게 혈액 종양에서 HDM2-p53 상호작용 억제제의 용량 및 요법
US11612604B2 (en) * 2017-12-06 2023-03-28 Ludwig Institute For Cancer Research Ltd Methods of treating cancer with PLK4 inhibitors
EP3959209A4 (en) 2019-04-24 2022-12-28 University Health Network S4 CRYSTALLINE FORM OF A PLK4 INHIBITOR (1R,2S)-(E)-2-(3-(4-((CIS-2,6-DIMETHYLMORPHOLINO)METHYL)STYRYL)-1H-IMIDAZOL-6-YL )-5'-METHOXYSPIRO[CYCLOPROPANE-L,3'-INDOLIN]-2'-ONE FUMARATE

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019046949A1 (en) * 2017-09-08 2019-03-14 University Health Network POLYTHERAPIES FOR INHIBITING KINASE 4 OF THE POLO TYPE

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
期刊 Zhao Y, et al. "Targeting polo-like kinase 4 for therapeutic benefit in the patients with diffuse large B-cell lymphoma" Blood 134(suppl 1): 2019/11/13; 2568
網路文獻 University Health Network, NCT03187288 "Study of CFI-400945 fumarate in patients with relapsed or refractory AML of MDS", ClinicalTrials.gov. version date:2018/8/13 https://clinicaltrials.gov/study/NCT03187288?tab=history&a=5#version-content-panel
網路文獻 University Health Network, NCT03187288 "Study of CFI-400945 fumarate in patients with relapsed or refractory AML of MDS", ClinicalTrials.gov. version date:2018/8/13 https://clinicaltrials.gov/study/NCT03187288?tab=history&a=5#version-content-panel;期刊 Zhao Y, et al. "Targeting polo-like kinase 4 for therapeutic benefit in the patients with diffuse large B-cell lymphoma" Blood 134(suppl 1): 2019/11/13; 2568 *

Also Published As

Publication number Publication date
AU2020396807A1 (en) 2022-07-21
JP2023505301A (ja) 2023-02-08
US12533357B2 (en) 2026-01-27
EP4069246A1 (en) 2022-10-12
MX2022006910A (es) 2022-11-09
US20230010772A1 (en) 2023-01-12
CA3163796A1 (en) 2021-06-10
IL293623A (en) 2022-08-01
CN115397429A (zh) 2022-11-25
BR112022011052A2 (pt) 2022-08-16
EP4069246A4 (en) 2023-12-06
WO2021108918A1 (en) 2021-06-10
TW202134237A (zh) 2021-09-16
AU2020396807B2 (en) 2026-07-16
KR20220124177A (ko) 2022-09-13

Similar Documents

Publication Publication Date Title
US12533357B2 (en) Treatment for acute myeloid leukemia or myelodysplastic syndrome
AU2012321110A1 (en) Combination treatment
JP7266030B2 (ja) リンパ球悪性疾患を治療するための方法
JP2017522281A (ja) キノリン誘導体による軟部組織肉腫の治療方法と用途、及び軟部組織肉腫治療するための薬用組成物
WO2013184621A1 (en) Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
BG107843A (bg) Ефективно антитуморно лечение
IL298200A (en) Combination therapy for treatment of myeloproliferative neoplasms
US20260137695A1 (en) Combination therapy for treatment of myeloproliferative neoplasms
CN115038447A (zh) 用于治疗癌症的组合疗法
US20230132982A1 (en) Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma
TWI849001B (zh) Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物
US20250049787A1 (en) Treatment for acute myeloid leukemia or lymphoma
EA049792B1 (ru) Лечение острого миелоидного лейкоза или миелодиспластического синдрома
TW202308641A (zh) 用於治療癌症之方法及包含cdk抑制劑之給藥方案
HK40085748A (en) Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma
CN121969369A (zh) Parp-1选择性抑制剂和替莫唑胺的组合及其治疗神经胶质瘤的用途
AU2022407330A1 (en) Combination therapy comprising a pkc inhibitor and a c-met inhibitor
AU2014264318B2 (en) Combination of a PI3 kinase inhibitor with paclitaxel for use in the treatment or prevention of a cancer of the head and neck